[go: up one dir, main page]

MA31381B1 - Vaccin contre la grippe a emulsion huile dans l'eau - Google Patents

Vaccin contre la grippe a emulsion huile dans l'eau

Info

Publication number
MA31381B1
MA31381B1 MA32351A MA32351A MA31381B1 MA 31381 B1 MA31381 B1 MA 31381B1 MA 32351 A MA32351 A MA 32351A MA 32351 A MA32351 A MA 32351A MA 31381 B1 MA31381 B1 MA 31381B1
Authority
MA
Morocco
Prior art keywords
water emulsion
level below
oil
influenza
vaccine against
Prior art date
Application number
MA32351A
Other languages
Arabic (ar)
English (en)
Inventor
William Ripley Ballou
Emmanuel Jules Hanon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707697A external-priority patent/GB0707697D0/en
Priority claimed from GB0711357A external-priority patent/GB0711357D0/en
Priority claimed from GB0712062A external-priority patent/GB0712062D0/en
Priority claimed from PCT/EP2007/060743 external-priority patent/WO2008043774A1/fr
Priority claimed from GB0724651A external-priority patent/GB0724651D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA31381B1 publication Critical patent/MA31381B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition immunogénique contre la grippe dans un volume de dose appropriée à l'usage humain, comprenant un antigène du virus de la grippe ou une préparation antigénique de celui-ci et une composition adjuvante comprenant une émulsion huile dans l'eau, dans laquelle ladite émulsion huile dans l'eau comprend une huile métabolisable à un niveau inférieur à 1 1 mg et un agent émulsifiant à un niveau inférieur à 5 mg et, de manière facultative, un tocol ou un stérol à un niveau inférieur à 12 mg. De manière appropriée, la quantité d'antigène de la grippe par souche par dose est de 15 μg ha ou une quantité inférieure à 15 μg ha.
MA32351A 2007-04-20 2009-11-17 Vaccin contre la grippe a emulsion huile dans l'eau MA31381B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0707697A GB0707697D0 (en) 2007-04-20 2007-04-20 Vaccine
GB0711357A GB0711357D0 (en) 2007-06-12 2007-06-12 Vaccine
GB0712062A GB0712062D0 (en) 2007-06-21 2007-06-21 Vaccine
PCT/EP2007/060743 WO2008043774A1 (fr) 2006-10-12 2007-10-10 Vaccin
GB0724651A GB0724651D0 (en) 2007-12-18 2007-12-18 Vaccine
PCT/EP2008/054614 WO2008128939A1 (fr) 2007-04-20 2008-04-16 Vaccin contre la grippe à émulsion huile dans l'eau

Publications (1)

Publication Number Publication Date
MA31381B1 true MA31381B1 (fr) 2010-05-03

Family

ID=39766893

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32351A MA31381B1 (fr) 2007-04-20 2009-11-17 Vaccin contre la grippe a emulsion huile dans l'eau

Country Status (21)

Country Link
US (4) US9452209B2 (fr)
EP (2) EP2455101A3 (fr)
JP (1) JP2010524883A (fr)
KR (1) KR101188382B1 (fr)
CN (2) CN101678096A (fr)
AR (1) AR066405A1 (fr)
AT (1) ATE537841T1 (fr)
AU (1) AU2008240761B2 (fr)
BR (1) BRPI0810015B1 (fr)
CA (1) CA2683075C (fr)
CO (1) CO6251369A2 (fr)
CR (1) CR11122A (fr)
DO (1) DOP2009000239A (fr)
EA (1) EA024250B1 (fr)
ES (1) ES2377761T3 (fr)
IL (1) IL200859A (fr)
MA (1) MA31381B1 (fr)
PE (1) PE20090146A1 (fr)
TW (1) TW200908994A (fr)
WO (1) WO2008128939A1 (fr)
ZA (1) ZA200906753B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2371994C (fr) * 1999-02-26 2010-09-28 Guido Grandi Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
MX2007011756A (es) * 2005-03-23 2008-03-11 Glaxosmithkline Biolog Sa Uso de un virus de la gripe y un adyuvante de emulsion de aceite en agua para inducir la respuesta mejorada de la celulas b de memoria y/o celulas t cd4.
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052155A2 (fr) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
MX2009003325A (es) * 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
BRPI0914224A2 (pt) 2008-06-19 2019-09-24 Variation Biotechnologies Inc composições e métodos para tratar a gripe
CN102159242A (zh) 2008-09-18 2011-08-17 诺华有限公司 疫苗佐剂组合
KR20110132373A (ko) * 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
EP3173097A3 (fr) 2009-02-10 2017-07-12 Seqirus UK Limited Vaccins contre la grippe dotés de quantités réduites de squalène
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN102656455B (zh) * 2009-10-21 2015-03-11 由卫生福利和体育大臣代表的荷兰王国 用于诊断针对病毒的免疫应答的方法
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CN102802662A (zh) 2010-03-18 2012-11-28 诺华有限公司 用于脑膜炎球菌血清组b的含佐剂疫苗
WO2011130652A2 (fr) * 2010-04-15 2011-10-20 George Baer Compositions et méthodes pour la vaccination d'humains et d'animaux contre des virus enveloppés
PL2575872T3 (pl) * 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2585106A1 (fr) 2010-06-25 2013-05-01 Novartis AG Associations de protéines de liaison du facteur h méningococcique
EP2667852B1 (fr) * 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Nanoémulsions d'adjuvant à inhibiteurs de cristallisation
WO2012114323A1 (fr) * 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Polypeptides multimères multi-épitopes utilisés dans des vaccins contre la grippe saisonnière et pandémique
WO2012116714A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des patients âgés
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US20140248320A1 (en) * 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
JP5918870B2 (ja) * 2012-03-06 2016-05-18 クルセル ホランド ベー ヴェー インフルエンザに対する改善されたワクチン接種
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2016104584A1 (fr) * 2014-12-25 2016-06-30 第一三共株式会社 Composition de vaccin anti-grippe à utiliser par voie intradermique
MX2019007349A (es) * 2016-12-23 2019-09-05 Intervet Int Bv Vacuna combinada para cerdos.
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
AU2018219437B2 (en) 2017-02-13 2023-03-02 Boehringer lngelheim Vetmedica GMBH Liquid applicator for delivering vaccines
CA3127639A1 (fr) * 2019-01-30 2020-08-06 Glaxosmithkline Biologicals Sa Melanges huile/tensioactif pour auto-emulsification
JP2022521760A (ja) * 2019-02-28 2022-04-12 ノババックス，インコーポレイテッド Ｒｓｖ感染によって引き起こされる疾患又は障害を予防する方法
CN114096273A (zh) * 2019-03-04 2022-02-25 日本国立感染症研究所所长代表之日本国 用于生产流感ha裂解疫苗的方法
KR20220036909A (ko) * 2019-04-06 2022-03-23 알티뮨 인크. 광범위하고 오래 지속되는 인플루엔자 백신
RU2740751C1 (ru) * 2019-08-28 2021-01-20 Общество с ограниченной ответственностью "Развитие БиоТехнологий" Способ получения тетравалентной субъединичной противогриппозной вакцины
CN113827715B (zh) * 2020-06-23 2024-07-05 普莱柯生物工程股份有限公司 一种抗h7亚型和h5亚型禽流感病毒的疫苗组合物、及其制备方法和应用
AU2021370895A1 (en) 2020-10-29 2023-06-08 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
KR20240076825A (ko) * 2021-10-08 2024-05-30 사노피 파스퇴르 인크 다가 인플루엔자 백신
KR20240033309A (ko) * 2022-09-05 2024-03-12 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
US4454119A (en) 1981-06-29 1984-06-12 Mitsubishi Chemical Industries Limited Therapeutic agents
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
FI69639C (fi) 1982-07-02 1986-03-10 Orion Yhtymae Oy Preparat foer anvaendning vid klamydia-diagnostik
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (fr) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer
EP0304578B1 (fr) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide contenant l'antigène de surface de l'hépatite B
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
DE69015222T2 (de) 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
DE69031556T2 (de) 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigene sowie Verfahren zu deren Herstellung
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5969109A (en) 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5030115A (en) 1990-07-23 1991-07-09 Molex Incorporated Tired socket assembly with integral ground shield
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
SG48390A1 (en) 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
WO1994019013A1 (fr) 1993-02-19 1994-09-01 Smithkline Beecham Corporation Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
HU219810B (hu) 1993-11-17 2001-08-28 Deutsche Om Arzneimittel Gmbh. Glükózamin-diszacharidok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények, valamint alkalmazásuk
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3836874B2 (ja) 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
EP1167377B2 (fr) 1994-07-15 2012-08-08 University of Iowa Research Foundation Oliogonucléotides immunomodulateurs
US5629052A (en) 1995-02-15 1997-05-13 The Procter & Gamble Company Method of applying a curable resin to a substrate for use in papermaking
WO1996026277A1 (fr) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998050567A1 (fr) 1997-05-02 1998-11-12 Abbott Laboratories Reactifs et procedes pour detecter les maladies de la prostate
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1279401B1 (fr) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
KR100766016B1 (ko) 1998-06-30 2007-10-11 옴 파르마 아실 유사디펩티드, 이의 제조 방법 및 이를 함유하는 약제 조성물
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
JP2003529559A (ja) 2000-01-31 2003-10-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規用途
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (fr) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
CA2438942A1 (fr) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Formulations d'un vaccin contre la grippe pour livraison intradermale
ATE404561T1 (de) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co Neue adeninderivate
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
DK1719511T3 (da) 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
US20040074760A1 (en) * 2002-10-17 2004-04-22 Carnegie Mellon University Production of biofuels
DE602004020189D1 (de) 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
CN1522691A (zh) * 2003-09-05 2004-08-25 韦怀新 核酸、蛋白多肽及疫苗乳剂的制备方法
EP1722815A1 (fr) 2004-03-09 2006-11-22 Chiron Corporation Vaccins antigrippaux
MX2007011756A (es) * 2005-03-23 2008-03-11 Glaxosmithkline Biolog Sa Uso de un virus de la gripe y un adyuvante de emulsion de aceite en agua para inducir la respuesta mejorada de la celulas b de memoria y/o celulas t cd4.
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
DK2422810T3 (da) * 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
MX2009003325A (es) * 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
WO2009071633A1 (fr) 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Composition contre la grippe
JP5756087B2 (ja) * 2009-04-21 2015-07-29 ダウ テクノロジー インベストメンツ リミティド ライアビリティー カンパニー 高効率触媒による特定のアルキレンオキサイド製造パラメーターを達成かつ維持する改良方法

Also Published As

Publication number Publication date
CA2683075A1 (fr) 2008-10-30
US10016495B2 (en) 2018-07-10
EP2455101A2 (fr) 2012-05-23
BRPI0810015B1 (pt) 2021-12-14
CA2683075C (fr) 2015-11-10
US20100189741A1 (en) 2010-07-29
IL200859A (en) 2015-10-29
ES2377761T3 (es) 2012-03-30
EA024250B1 (ru) 2016-08-31
AU2008240761B2 (en) 2014-05-29
ZA200906753B (en) 2010-12-29
CO6251369A2 (es) 2011-02-21
US20090136543A1 (en) 2009-05-28
US10548969B2 (en) 2020-02-04
WO2008128939A1 (fr) 2008-10-30
CN105311629A (zh) 2016-02-10
AU2008240761A1 (en) 2008-10-30
EA200901161A1 (ru) 2010-06-30
TW200908994A (en) 2009-03-01
EP2136837B1 (fr) 2011-12-21
AR066405A1 (es) 2009-08-19
ATE537841T1 (de) 2012-01-15
PE20090146A1 (es) 2009-03-23
DOP2009000239A (es) 2009-11-15
CR11122A (es) 2010-03-22
EP2455101A3 (fr) 2013-04-24
US20170246290A1 (en) 2017-08-31
BRPI0810015A2 (pt) 2014-10-14
KR101188382B1 (ko) 2012-10-08
EP2136837A1 (fr) 2009-12-30
IL200859A0 (en) 2010-05-17
JP2010524883A (ja) 2010-07-22
KR20100009576A (ko) 2010-01-27
US20180339037A1 (en) 2018-11-29
US9597389B2 (en) 2017-03-21
CN101678096A (zh) 2010-03-24
US9452209B2 (en) 2016-09-27

Similar Documents

Publication Publication Date Title
MA31381B1 (fr) Vaccin contre la grippe a emulsion huile dans l'eau
MA30023B1 (fr) Nouvelle composition
MA29715B1 (fr) Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b
MA30866B1 (fr) Vaccin
MA30624B1 (fr) Vaccin anti-grippal
Wedemeyer et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection
NZ592713A (en) Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
MXPA05008838A (es) Formulaciones de absorcion acelerada del agonista selectivo de la 5-ht.
RU2011130526A (ru) Композиции для введения лекарственных средств
Boyle et al. The utility of ISCOMATRIX™ adjuvant for dose reduction of antigen for vaccines requiring antibody responses
EA201001479A1 (ru) Вакцина
MX2010004271A (es) Formulaciones de vacuna meningococica.
MA29601B1 (fr) Vaccin antipaludeen
BRPI0509086A (pt) uso de inibidores de pde iii para redução do tamanho do coração em mamìferos sofrendo de parada cardìaca
Nakagami et al. Potential effect of angiotensin II receptor blockade in adipose tissue and bone
BRPI0518091A2 (pt) mycobacterium, mÉtodo para permitir com que uma mycobacterium escape a partir de endossomos e preparaÇço para uma vacina
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
Gane et al. FOUR YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB), PRELIMINARY ANALYSIS: 481
MX2009010963A (es) Vacuna de influenza de emulsion de aceite en agua.
Ng et al. Lipopeptide vaccines illustrate the potential role of subtype‐crossreactive T cells in the control of highly virulent influenza
EP2433648A3 (fr) Vaccin comprenant une émulsion adjuvante huile en l'eau
UY31024A1 (es) Vacuna